ARTEMISMED Share Price Target 2030

CAGR-based price projection for Artemis Medicare Services Limited (ARTEMISMED) targeting 2030, derived from official NSE exchange closing prices.

Bear Case (18.6% CAGR)
Rs 667
2030 Target
Base Case (46.6% CAGR)
Rs 1,555
2030 Target
Bull Case (149.5% CAGR)
Rs 13,032
2030 Target

Current Market Snapshot

CMP: Rs 336.40
52W High: Rs 366.60
52W Low: Rs 228.20
1Y CAGR: 115.0%
3Y CAGR: 46.6%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 399 Rs 493 Rs 839
2028 Rs 474 Rs 723 Rs 2,094
2029 Rs 562 Rs 1,060 Rs 5,224
2030 Rs 667 Rs 1,555 Rs 13,032

Other ARTEMISMED Price Targets

2025 2026 2027 2028 2035 2040 2050

Frequently Asked Questions

What is the ARTEMISMED share price target for 2030?

Based on historical growth analysis, the ARTEMISMED share price target for 2030 ranges from Rs 667 (conservative) to Rs 1,555 (base case) to Rs 13,032 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of ARTEMISMED?

The current market price of ARTEMISMED (Artemis Medicare Services Limited) is Rs 336.40. The 52-week high is Rs 366.60 and 52-week low is Rs 228.20.

Is ARTEMISMED a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for ARTEMISMED price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 18.6% CAGR), Base (46.6% CAGR), and Bull (optimistic at 149.5% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.